# Avalus Ultra Post-Approval Study (PAS)

Study · id `cardio:ct-nct06506903` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06506903](<https://clinicaltrials.gov/study/NCT06506903>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06506903

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 190 participants.

## Technical summary

Registry record NCT06506903. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-20 (actual); primary completion 2026-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 190 participants (enrolled count; ClinicalTrials.gov record NCT06506903, source copy `cardio:ctgov-nct06506903-2026-04-21`, retrieved 2026-10-26)
- Started: 2024-11-20 (actual) (ClinicalTrials.gov record NCT06506903, source copy `cardio:ctgov-nct06506903-2026-04-21`, retrieved 2026-10-26)
- Primary completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT06506903, source copy `cardio:ctgov-nct06506903-2026-04-21`, retrieved 2026-10-26)
- Completion: 2026-11 (anticipated) (ClinicalTrials.gov record NCT06506903, source copy `cardio:ctgov-nct06506903-2026-04-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06506903, source copy `cardio:ctgov-nct06506903-2026-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06506903-2026-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Avalus Ultra Post-Approval Study (PAS)
- Condition: Aortic Valve Disease
- Intervention (Device): Medtronic Avalus Ultra
- Lead sponsor: Medtronic Cardiac Surgery
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Medtronic Cardiac Surgery (`cardio:org-medtronic-cardiac-surgery`)

## Provenance

Content hash: 7d50f3cd29d51e53015e8ce45696e1c2574a86dc373728c66bb75b696db22e94
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
